Division of Takeda Pharmaceutical Co. Ltd.
Latest From Jerini AG
Syncona-backed Freeline has nabbed an "accomplished commercial leader" in Theresa Heggie to lead the company as it prepares to take FLT180a, its gene therapy for hemophilia B, into Phase III.
Shire’s Perry Sternberg and Phil Vickers are optimistic about recent launches and products in late stages of development in key rare disease and specialty therapeutic areas, many of which come from Baxalta and other high-profile acquisitions.
For larger organizations with interests in rare diseases, Bionest Partners believes it is necessary to maintain a separation from the rest of the company in order to keep the culture needed for successful product commercialization. Easier said than done.
Shire Pharmaceuticals is known for its acquisitive buy-late, maximize-market strategy. Flemming Ornskov, the company's new CEO, plans to continue that approach, firstly by applying it to acquisitions in ophthalmology, an area in which he has specialized. However, with many recent acquisitions yet to mature to revenue-generation, and with big indication areas for Shire like ADHD at risk from generic and branded competition, the pressure is on the new CEO – even before he officially starts work.
- Large Molecule
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Takeda Pharmaceutical Co. Ltd.
- Senior Management
Jens Schneider-Mergener, PhD, CEO
Berndt Modig, CFO
Christiane Hanke-Harloff, PhD, VP, Sales & Mktg.
Jochen Knolle, CSO
- Contact Info
Phone: (49) 30-978 93-0